From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
Meridian is committed to helping developers build assays that not only perform but also transform cancer care for patients everywhere. Learn more about our Solutions for Next-Generation Sequencing and our Custom Enzyme Stabilization Services
While advanced sequencing platforms are expanding the reach of molecular oncology, quantitative PCR remains the most trusted frontline tool for early detection—thanks to its proven strengths in sensitivity, speed, and accessibility. From rapid mutation detection to deep tumor profiling, qPCR, tNGS, and WGS each serve a critical role in the evolving precision oncology landscape. But the success of any platform depends on what powers it. As a partner to References 1. Roychowdhury, S. & Chinnaiyan, A. M. (2014). Translating genomics for precision cancer medicine. Annual Review of Genomics and Human Genetics , 15, 395-415. https://doi. org/10.1146/annurev-genom-090413-025552 2. U.S. Food and Drug Administration. (n.d.). List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Retrieved June 5, 2025, from https://www.fda.gov/ medical-devices/in-vitro-diagnostics/list-cleared-or-approved- companion-diagnostic-devices-in-vitro-and-imaging-tools
leading assay developers, Meridian provides the technical expertise and reagent stability needed for diagnostic scale-up. Glycerol-free enzymes, lyophilization-ready master mixes, and customized formulation services are helping developers address common barriers—such as cold-chain logistics, inhibitor sensitivity, and long-term reagent stability. These innovations enable robust assay performance across diverse clinical settings, supporting the global delivery of high-impact diagnostic tools. n
3. Merker, J. D., et al. (2018). Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. Journal of Clinical Oncology , 36(16), 1631-1641. https://doi.org/10.1200/JCO.2017.76.8671 4. Frampton, G. M., et al. (2013). Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotechnology, 31(11), 1023- 1031. https://doi.org/10.1038/nbt.2696
GENengnews.com | 19
Powered by FlippingBook